Overarching research question

What are the key components and characteristics of a successful cessation program at low-dose CT lung cancer screening?

Outcome: long-term cigarette smoking abstinence
Examples of research questions

• Does the success of specific cessation methods differ by:
  – individual characteristics?
  – exam results? *If scan is unremarkable, is patient less likely to quit smoking?*

• How do approaches compare with respect to intervention fidelity, patient reach, cost, cost-effectiveness, ease of delivery?
RFA CA-15-011

- Innovative intervention or implementation focus
- Developing/testing delivery models
- Comparative design
- Common measures
- Dissemination

R01 awards funded September 2016

NCI Board of Scientific Advisors Meeting presentation, Smoking Cessation within the Context of Lung Cancer Screening RFA Concept (beginning at 4:49:50). March 2015.
Smoking Cessation at Lung Examination (SCALE) Collaboration

- 8 Trials (5 RFA-funded trials and 3 additional projects)
- Share data and methods using common measures for cross-project research

1. Cinciripini (MD Anderson)
2. Foley/Chiles (Wake Forest)
3. Joseph (U Minnesota)
4. Ostroff/Shelley (Memorial Sloan Kettering)
5. Park/Rigotti/Haas (Partners/MGH)
6. Taylor (Georgetown)
7. Toll (MUSC)
8. Zeliadt (Fred Hutchinson)
## SCALE Interventions

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Cinciripini</th>
<th>Foley</th>
<th>Park</th>
<th>Toll</th>
<th>Ostroff</th>
<th>Zeliadt</th>
<th>Joseph</th>
<th>Taylor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Counseling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telephone counseling</td>
<td></td>
<td></td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motivational Interviewing</td>
<td>☐</td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobile health</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Video</td>
<td></td>
<td></td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gain/loss framing</td>
<td></td>
<td>☐</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRT</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Pharmacotherapy</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Quitline</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Community resources</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Pharmacist training</td>
<td></td>
<td></td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
SCALE Measures Special Collection

- Demographics and personal experiences
- Family medical history
- Psychological variables (depression, perceived personal risk, lung cancer worry)
- Smoking behavior and attitudes
- Implementation of cessation intervention
- Medical outcomes
- Organizational characteristics

https://cancercontrol.cancer.gov/brp/tcrb/scale-collaboration.html
SCALE Progress – Publications and Presentations


- Land: APOS, 2015; ERS, 2017; IASLC, 2017; Alliance, 2017; U. Pittsburgh, 2018
SCALE Progress

- 3,347 patients enrolled as of 12/2019
- Annual grantee meetings; monthly conference calls
- Data sharing
  - Managed, housed by NCI
  - Annual Special Measures Collection and ad hoc
  - 7 of 8 projects submitted during 2019 (N=2,583)
- Abstracts submitted for 2020 conferences
- 6 active cross-project research efforts
- CHALLENGE: Recruitment! (Strategies: shared materials, Recruitment Innovation Center - Vanderbilt)
Smoking Cessation at Lung Examination: The SCALE Collaboration

“The question is not whether. The question is how to provide cessation services in the setting of lung cancer screening.”

– Stephanie Land, Ph.D., Behavioral Research Program
Discussion

• Goal is that SCALE will produce set of cessation packages and information about which are best for a given LDCT clinic.
• Uptake of lung cancer screening, and of LDCT participants in cessation, are barriers.
• There remains a need for other research related to cessation and LDCT.
Contact:
Stephanie.land@nih.gov
Stay connected with us!

Sign up for our NCI Behavioral Research Program email updates at:
cancercontrol.cancer.gov/brpsubscribe
Follow us on Twitter: @NCIBehaviors